April 19, 2012

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson’s Disease

- Fox Foundation to sponsor a clinical trial to study Sanofi compound -

 

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson’s Disease
- Fox Foundation to sponsor a clinical trial to study Sanofi compound -

Paris, France – April 19, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor – phosphodiesterase type 4 inhibitor – in patients with Parkinson’s disease (PD).